Cited by 26Health Systems, Economic Evaluations, Quality of LifeCervical Cancer and HPV ResearchSimulation Techniques and Applications

The DOI matches its Crossref record, with a small difference in title or year.

Incorporating Calibrated Model Parameters into Sensitivity Analyses: Deterministic and Probabilistic Approaches

Abstract

Objective The aim of this study was to examine how calibration uncertainty affects the overall uncertainty of a mathematical model and to evaluate potential drivers of calibration uncertainty. Methods A lifetime Markov model of the natural history of human papillomavirus (HPV) infection and cervical disease was developed to assess the cost effectiveness of a hypothetical HPV vaccine. Published data on cervical cancer incidence and mortality and prevalence of pre-cursor lesions were used as endpoints to calibrate the age- and HPV-type-specific transition probabilities between health states using the Nelder-Mead simplex method of calibration. A conventional probabilistic sensitivity analysis (PSA) was performed to assess uncertainty in vaccine efficacy, cost and utility estimates. To quantify the uncertainty around calibrated transition probabilities, a second PSA (calibration PSA) was performed using 25 distinct combinations of objective functions and starting simplexes. Results The initial calibration produced an incremental cost-effectiveness ratio (ICER) of $US 4300 per QALY for vaccination compared with no vaccination, and the conventional PSA gave a 95% credible interval of dominant to $US 9800 around this estimate (2005 values). The 95% credible interval for the ICERs in the calibration PSA ranged from $US 1000 to $US 37,700. Conclusions Compared with a conventional PSA, the calibration PSA results reveal a greater level of uncertainty in cost-effectiveness results. Sens…

Overview

Integrity signals

Registry

Crossref · 10.2165/11593360-000000000-00000

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • For more complex models, standard calibration approaches can be applied to identify the best fitting set of inputs, or multiple sets of values, which can then form the basis for uncertainty analysis.

    “For more complex models, standard calibration approaches can be applied to identify the best fitting set of inputs, or multiple sets of values, which can then form the basis for uncertainty analysis [18 -21].”

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 19

  1. Weinstein, 2006, Pharmacoeconomics, 24, 1043, 10.2165/00019053-200624110-00002 · DOI · Paper page
  2. Clarke, 2006, J Natl Cancer Inst Monogr, 36, 96, 10.1093/jncimonographs/lgj013 · DOI
  3. Vanni, 2011 Jan 1, Pharmacoeconomics, 29, 35, 10.2165/11584600-000000000-00000 · DOI · Paper page
  4. Taylor, 2011 Jul-Aug, Value Health, 14, 700, 10.1016/j.jval.2011.01.002 · DOI
  5. Kohli, 2007, Br J Cancer, 96, 143, 10.1038/sj.bjc.6603501 · DOI
  6. Benard, 2004, Obstet Gynecol, 103, 564, 10.1097/01.AOG.0000115510.81613.f0 · DOI
  7. Nelder, 1965, Comput J, 7, 308, 10.1093/comjnl/7.4.308 · DOI · Paper page
  8. Taylor, 2010 Nov 1, Pharmacoeconomics, 28, 995, 10.2165/11538660-000000000-00000 · DOI
  9. Stout, 2009, Pharmacoeconomics, 27, 533, 10.2165/11314830-000000000-00000 · DOI
  10. Fryback, 2006, J Natl Cancer Inst Monogr, 36, 37, 10.1093/jncimonographs/lgj007 · DOI
  11. Urban, 1997 Jun, Control Clin Trials, 18, 251, 10.1016/S0197-2456(96)00233-4 · DOI
  12. Berkhof, 2005 Jun 10, Int J Cancer, 115, 268, 10.1002/ijc.20846 · DOI
  13. Kim, 2007, Am J Epidemiol, 166, 137, 10.1093/aje/kwm086 · DOI · Paper page
  14. Van de Velde, 2007 Apr 1, Am J Epidemiol, 165, 762, 10.1093/aje/kwk059 · DOI
  15. Goldhaber-Fiebert, 2007 Oct 29, Population Health Metrics, 5, 11, 10.1186/1478-7954-5-11 · DOI
  16. Jit, 2008, BMJ, 337, a769, 10.1136/bmj.a769 · DOI
  17. Karnon, 2009 May-Jun, Med Decis Making, 29, 304, 10.1177/0272989X08327491 · DOI · Paper page
  18. Rutter, 2009 Dec 1, J Am Stat Assoc, 104, 1338, 10.1198/jasa.2009.ap07466 · DOI
  19. Stout, 2006, J Natl Cancer Inst, 98, 774, 10.1093/jnci/djj210 · DOI

Cited by

Sorted by citations

Metadata

Authors
Taylor, D. C. A., Pawar, V., Kruzikas, D. T., Gilmore, K. E., Sanon, M., & Weinstein, M. C.
Affiliations
  • GlaxoSmithKline (United States) (US)
  • Harvard University (US)
Corresponding author
Taylor, Douglas C.A.
Venue
PharmacoEconomics
Published
2012-02
Volume
30
Issue
2
Pages
119-126
ISSN
1170-7690 (ISSN-L)
OpenAlex
W1487480195
Cited by
26
References
0
Citations by year
2025: 2 · 2024: 1 · 2023: 1 · 2022: 1 · 2021: 1 · 2020: 2 · 2019: 2 · 2018: 2 · 2017: 2 · 2016: 1 · 2015: 3 · 2014: 4 · 2013: 1 · 2012: 2
FWCI
5.68
Type
journal article
Language
en
Open access
closed
Locations
  • PharmacoEconomics (publishedVersion)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
Funders
  • GlaxoSmithKline
  • Bayer HealthCare
Topics
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
  • Social Sciences › Decision Sciences › Management Science and Operations Research › Simulation Techniques and Applications
Keywords
model calibration, calibration uncertainty, probabilistic sensitivity analysis, HPV vaccine, human papillomavirus, cervical cancer, cervical precancerous lesions, Markov model, cost-effectiveness, transition probabilities, Nelder-Mead algorithm, incremental cost-effectiveness ratio
MeSH terms
Adolescent, Adult, Age Factors, Aged, Aged, 80 and over, Calibration, Uterine Cervical Dysplasia, Uterine Cervical Neoplasms, Computer Simulation, Cost-Benefit Analysis, Female, Humans, Markov Chains, Middle Aged, Models, Biological, Incidence, Prevalence, Likelihood Functions, Models, Economic, Quality-Adjusted Life Years, Papillomavirus Infections, Uncertainty, Papillomavirus Vaccines, Young Adult, Neoplasm Grading

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review